Lysophospholipid receptor nomenclature review: IUPHAR Review 8. (12th July 2014)

• Record Type: Journal Article
• Authors: Kihara, Yasuyuki; Maceyka, Michael; Spiegel, Sarah; Chun, Jerold
• Is Part Of: British journal of pharmacology. Volume 171:Number 15(2014:Aug.)
• Page Start: 3575
• Page End: 3594
• Publication Date: 2014-07-12
• Subjects: Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.12678
• Languages: English
• ISSNs: 0007-1188

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Lysophospholipids encompass a diverse range of small, membrane‐derived phospholipids that act as extracellular signals. The signalling properties are mediated by 7‐transmembrane GPCRs, constituent members of which have continued to be identified after their initial discovery in the mid‐1990s. Here we briefly review this class of receptors, with a particular emphasis on their protein and gene nomenclatures that reflect their cognate ligands. There are six lysophospholipid receptors that interact with lysophosphatidic acid (LPA): protein names LPA<sub>1</sub> – LPA<sub>6</sub> and italicized gene names <italic>LPAR1‐LPAR6</italic> (human) and <italic>Lpar1‐Lpar6</italic> (non‐human). There are five sphingosine 1‐phosphate (S1P) receptors: protein names S1P<sub>1</sub>‐S1P<sub>5</sub> and italicized gene names <italic>S1PR1‐S1PR5</italic> (human) and <italic>S1pr1‐S1pr5</italic> (non‐human). Recent additions to the lysophospholipid receptor family have resulted in the proposed names for a lysophosphatidyl inositol (LPI) receptor – protein name LPI<sub>1</sub> and gene name <italic>LPIR1</italic> (human) and <italic>Lpir1</italic> (non‐human) – and three lysophosphatidyl serine receptors – protein names LyPS<sub>1</sub>, LyPS<sub>2</sub>, LyPS<sub>3</sub> and gene names <italic>LYPSR1‐LYPSR3</italic> (human) and <italic>Lypsr1‐Lypsr3</italic> (non‐human) along with a variant form that does not appear to exist in humans that is provisionally named LyPS<sub>2L</sub>. This nomenclature incorporates previous recommendations from the International Union of Basic and Clinical Pharmacology, the Human Genome Organization, the Gene Nomenclature Committee, and the Mouse Genome Informatix.</p> </abstract>